Evidence map›Paper›PMID 25982630›Full record

ReviewActa pharmacologica Sinica2015

Anti-tumor activities of active ingredients in Compound Kushen Injection.

Wei Wang, Rong-li You, Wen-jie Qin, Li-na Hai, Ming-jing Fang, Guo-hua Huang, Rui-xia Kang, Ming-hua Li, Yu-feng Qiao, Jian-wei Li and 1 more

Open access · bronzeAbstract readReview
In one paragraph

Review in Acta pharmacologica Sinica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 6 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 6 syntheses or guidelines pooled it, 171 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Unraveling the Therapeutic Potential ofCurrent pharmaceutical design · 2025
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Natural Product-Inspired Dopamine Receptor Ligands.Journal of medicinal chemistry · 2024
    Review
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Wei Wang1] Beijing Zhendong Guangming Pharmaceutical Research Institute Co Ltd, Beijing 100120, China [2] Shanxi Zhendong Pharmaceutical Co Ltd, Changzhi 047100, China [3] Gastroenterology Department, the Second People's Hospital of Zhuhai, Zhuhai 519000, China.
Rong-li You1] Beijing Zhendong Guangming Pharmaceutical Research Institute Co Ltd, Beijing 100120, China [2] Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Wen-jie QinBeijing Zhendong Guangming Pharmaceutical Research Institute Co Ltd, Beijing 100120, China.
Li-na HaiBeijing Zhendong Guangming Pharmaceutical Research Institute Co Ltd, Beijing 100120, China.
Ming-jing FangBeijing Zhendong Guangming Pharmaceutical Research Institute Co Ltd, Beijing 100120, China.
Guo-hua HuangDepartment of Respiration, Nanfang Hospital of Southern Medical University, Guangzhou 510515, China.
Rui-xia KangInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Ming-hua LiShanxi Zhendong Pharmaceutical Co Ltd, Changzhi 047100, China.
Yu-feng QiaoShanxi Zhendong Pharmaceutical Co Ltd, Changzhi 047100, China.
Jian-wei Li1] Shanxi Zhendong Pharmaceutical Co Ltd, Changzhi 047100, China [2] Department of Pharmacy, Chang Zhi Medical College, Changzhi 046000, China.
An-ping LiShanxi Zhendong Pharmaceutical Co Ltd, Changzhi 047100, China.
Shanxi Zhendong Pharmaceutical (China) · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNNanfang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kushen (Radix Sophorae Flavescentis) has a long history of use for the treatment of tumors, inflammation and other diseases in traditional Chinese medicine. Compound Kushen Injection (CKI) is a mixture of natural compounds extracted from Kushen and Baituling (Rhizoma Smilacis Glabrae). The main principles of CKI are matrine (MT) and oxymatrine (OMT) that exhibit a variety of pharmacological activities, including anti-inflammatory, anti-allergic, anti-viral, anti-fibrotic and cardiovascular protective effects. Recent evidence shows that these compounds also produce anti-cancer actions, such as inhibiting cancer cell proliferation, inducing cell cycle arrest, accelerating apoptosis, restraining angiogenesis, inducing cell differentiation, inhibiting cancer metastasis and invasion, reversing multidrug resistance, and preventing or reducing chemotherapy- and/or radiotherapy-induced toxicity when combined with chemotherapeutic drugs. In this review, we summarize recent progress in studying the anti-cancer activities of MT, OMT and CKI and their potential molecular targets, which provide clues and references for further study.

Indexed as

AlkaloidsAnimalsAntineoplastic Agents, PhytogenicDrugs, Chinese HerbalHumansInjectionsMatrinesMedicine, Chinese TraditionalNeoplasmsQuinolizinesTreatment OutcomeAlkaloidsAntineoplastic Agents, PhytogenicDrugs, Chinese HerbalkushenMatrinesoxymatrineQuinolizines

Identifiers

PMID25982630
PMCPMC4594177
OpenAlexW2098383911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.